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Abstract
Background
Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous reports showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction.
Design and Methods
In this study, we employed real-time quantitative PCR to examine minimal residual disease in 398 pairs of blood and marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with ALL IC-BFM 2002 protocol.
Results
At early treatment time points, we confirmed the previously published poor correlation between minimal residual disease in blood and marrow, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold, range 0.04-8,293-fold). A higher involvement of peripheral blood at diagnosis was associated with a higher white blood cell count at diagnosis (p=0.003) and with enlargement of the spleen (p=0.0004) and liver (p=0.05). At day 15, minimal residual disease in blood lower than 10 -4 was associated with an excellent five-year relapse-free survival in 78 investigated patients (100% vs. 69±7%; p=0.0003). Subgroups defined by the level of minimal residual disease in blood at day 15
(high-risk: , standard-risk: <10 -4 ) partially correlated with bone marrow-based stratification described previously, but the risk groups did not match completely. No other time point was predictive of outcome in peripheral blood, except for a weak association at day 8.
Introduction
Minimal residual disease (MRD) testing demonstrated great prognostic impact in childhood acute lymphoblastic leukemia (ALL) as early as a decade ago. [1] [2] [3] Since then, it has been implemented into the risk stratification of the most progressive childhood and adult ALL treatment protocols. [4] [5] [6] [7] [8] Bone marrow (BM) aspirates are consistently used for MRD evaluation based on both the medullar location of the disease and previous reports exploring the level of MRD in the peripheral blood (PB) relative to the BM. Several studies have proven that the levels of MRD in PB and BM correlate well in T-ALL, but observed a weak correlation and generally lower PB-MRD in B-cell precursor (BCP)-ALL.
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Surprisingly, only a few reports have explored the prognostic impact of MRD in PB, although PB aspiration is far more comfortable for both patients and clinicians. Brisco et al.
14 investigated whether PB-MRD could be used for the early detection of BM relapse and showed that MRD was detectable in the PB from all eight patients examined at least ten weeks prior to BM relapse. Coustan-Smith et al. 10 showed in a limited number of patients that patients having MRD detectable in both the PB and BM at the end of induction therapy (day 46) had a significantly higher incidence of relapse than patients with MRD in the BM only.
In this study, we investigated the prognostic impact of PB involvement during early time points of childhood ALL treatment using the Berlin-Frankfurt-Münster (BFM) ALL IC-BFM 2002 protocol. Table 1 ). We examined 398 pairs of PB and BM samples taken simultaneously at the following time points: diagnosis (n=93), d8 (n=83), and d15 (n=78) of induction, the end of induction phase 1 -d33 (n=53), pre-consolidation -w12 (n=47), prior to maintenance therapy (pre-MT, n=6), and at the end of maintenance therapy (post-MT, n=38).
Design and Methods
Patients
The median follow-up period of the study group was 6.3 years. The research was approved by the relevant institutional ethics committee. All patients or their parents or guardians gave an informed consent to participate in the study. The BM-MRD data from this cohort, but not their impact on relapse-free survival, were published as a part of a previous study exploring the relationship between BM-MRD and other risk factors. 15 Spleen and liver enlargements were evaluated by manual palpation during a neutral respiratory phase and the results were reported in cm below the costal margin in the mid-clavicular line.
Flow cytometry
Flow cytometry immunophenotyping of BM aspirates was performed at diagnosis using a recommended panel of monoclonal antibodies as described previously. 16 
DNA index
The DNA index was assessed routinely at diagnosis using the CycleTestPlus DNA Reagent kit (BD, San Jose) as previously described. 17, 18 The DNA index was defined as a ratio of the mode of fluorescence of cells in the G0/G1 phase and the mode of fluorescence of normal peripheral blood in the G0/G1 phase. Specimens with a DNA index ≥ 1.16 and ≤ 1.6 were labeled as hyperdiploid in this study.
Ikaros (IKZF1) deletions
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The presence of Ikaros (IKZF1) gene deletions was assessed by MLPA ® (multiplex ligationdependent probe amplification) according to the manufacturer's instructions (MRC Holland, kit P335). The results were evaluated using the Coffalyser v9.4 software.
MRD monitoring
The isolation of mononuclear cells from the diagnostic and follow-up BM and PB samples; the isolation of genomic DNA; the detection of Ig heavy chain (IgH), Ig light chain kappa (IgK), TCR gamma (TCRG), and TCR delta (TCRD) gene rearrangements by PCR amplification; heteroduplex analysis; and sequencing were performed as described previously. 15, [19] [20] [21] The design of the patient-specific RQ-PCR systems and the Ig/TCR genebased RQ-PCR MRD measurements were also described previously. 15, [22] [23] [24] [25] In all patients, at 
Statistical analysis
All statistical analyses were performed using StatView ® version 5.0 (StatView ® Software, Cary, NC) or Statistica software (Statsoft, Tulsa, USA). The distribution of variables between groups was assessed using the Chi-square or Fisher's exact test. The Mann Whitney test was used to estimate the significance of differences among continuous values. The correlation between BM-and PB-MRD levels in paired samples was assessed using the Spearman's correlation coefficient. Relapse-free survival was calculated from the date of diagnosis to the 6 last follow-up or to relapse. Rates were calculated according to the Kaplan-Meier method and compared by the log-rank test. Cox regression was used for the multivariate analysis.
Results
Peripheral blood involvement at diagnosis
Ig/TCR-based MRD monitoring uses diagnostic BM samples as a standard for quantification to which all follow-up MRD values are related (BM-MRD level at diagnosis is set to 1); therefore, no absolute quantification was possible. The level of relative PB disease correlated with the WBC at diagnosis. Patients with a leukocyte count of more than 20,000/μl at diagnosis, corresponding to the cut-off used in the ALL IC-BFM 2002 stratification, had a higher PB involvement at diagnosis than other patients (p=0.003, Figure 1A ). A higher PB involvement at diagnosis correlated with enlargement of the spleen (p=0.0004, Figure 1B ) and less significantly with enlargement of the liver (p=0.05, Figure 1C ).
Peripheral blood involvement during the course of initial treatment
As in previous studies, which were performed mostly on samples from later time points, we observed a poor correlation between PB-and BM-MRD levels at d8, d15, and d33 ( Figure 2 ).
Among 398 pairs of PB-BM samples, MRD was double-negative in 118 pairs (30%). In 240 paired samples, MRD was detectable in both tissues; in 34 and 6 pairs, MRD was detectable in only the BM and PB, respectively. The MRD levels in the PB varied enormously and were mostly lower than those in the BM, with a mean difference of 206-fold (0.04-to 8,293-fold, double-positive samples only). In 148/280 positive samples (53%), we observed more than a 1-log difference between BM-and PB-MRD. This correlation pattern did not differ among the study time points. In 34 PB-negative cases, BM values were positive with a median of 2.2x10 Figure 3 shows the levels of PB-MRD at d8, d15, and d33 with respect to the occurrence of relapse. The PB-MRD at d15 was clearly higher in patients who subsequently relapsed (p=0.0006, Figure 3B ). A similar yet less significant trend was found for d8 PB-MRD (p=0.02, Figure 3A) . At d8, PB-MRD provided only a weak prediction of RFS (p=0.06, using the cut-offs 10 -3 and 10 -2 for defining the low, intermediate and high-risk groups, Figure 4C ), while BM-MRD was not at all predictive with any cut-off that we applied ( Figure 4D ).
MRD in peripheral blood and outcome
MRD in peripheral blood at day 15 in risk group stratification
Consistent with previous reports, 28-32 BM-MRD levels at d15 were also predictive of the outcome. For defining three risk groups based on d15 BM-MRD, we used the cut-offs of 10 -1 and 5x10 -3 ( Figure 4B ). The MRD PB low group (35/78, 45%) had a similar size as the BM lowrisk group defined by a BM-MRD of less than 5x10 -3 (39/78, 50%), which comprised one relapsed patient.
As for the HR definition based on PB, patients having a d15 PB-MRD higher than 10 -2 had a 5-year RFS of only 51±20% ( Figure 4A ), similar to the patients with a BM-MRD higher than 10 -1 (56±17%, Figure 4B ). However, the difference between the HR and IR groups was not statistically significant for either BM or PB.
The correlation of d15 PB-MRD stratification using the cut-off 10 -4 with other risk factors is shown in The correlation with d15 BM-MRD subgroups was highly significant (p<0.0001, Chi square), but again, the groups did not match completely (Table 2) . Interestingly, the one patient who relapsed in the BM-MRD low-risk group (less than 10 -3
) would be classified as HR (more than 10 -2 ) according to PB.
To assess if d15 PB-MRD adds information to the current risk group stratification, we performed bi-variate Cox regression analysis, first using ALL IC-BFM 2002 protocol risk groups (based on age, WBC at diagnosis, prednisone response and BM morphology at d15), next using the BFM criteria based on combined BM-MRD information from d33 and w12.
Low PB-MRD at d15 (<10 -4 ) was prognostically significant both when added to the ALL IC criteria (HR, 0.08; 95% CI, 0.011-0.62; p=0.016) and the current BFM MRD criteria (HR, 0.12; 95% CI, 0.015-0.915; p=0.041).
Discussion
As in previous studies exploring later treatment time points, we also showed that in the early phase of B-cell precursor ALL treatment, PB involvement is highly variable and does not always reflect the situation in the BM. Despite this fact, our results showed that PB-MRD at d15 of the BFM-based treatment is related to the prognosis.
Starting with a quantitative assessment of diagnostic PB involvement relative to BM involvement, our study demonstrated that the level of PB disease correlates with the WBC at diagnosis, which is an expected result. Taking inter-observer bias into account, the finding that a higher PB involvement at diagnosis is related to enlargement of the spleen and liver likely reflects a similar connection with the WBC at diagnosis, which was observed in both ours and a previous study. 33 Of note, the initial leukemic cell mass, calculated as a continuous variable from the blast count in the blood at diagnosis and the size of the liver and spleen, was used for stratification in trials BFM-81, 83, 86, and 90. 34 One of the major goals of this work was to determine whether BM aspiration could be replaced by less invasive PB sampling at some of the examined time points. D15 seems to be the only candidate for further consideration because most of the samples were PB-MRD negative and thus did not provide any useful prognostic information at later time points (d33, w12, pre-MT, post-MT). PB aspiration at d8 has been established as a gold standard because of a highly predictive value of the cytomorphologically estimated "prednisone response" in 9 defining HR patients. 35, 36 A large study performed by the Children's Oncology Group has shown that patients with high levels of PB-MRD at d8, as measured by flow cytometry, had a relatively poor outcome even if they reached BM-MRD negativity by day 29. 37 However, due to a different protocol without the prednisone prephase, the MRD data are not directly comparable with our study.
The prognostic impact of d15 BM-MRD in BFM-based protocols has already been proven in several independent studies using either an Ig/TCR-based RQ-PCR approach 28, 29 or flow cytometry. [30] [31] [32] In a flow cytometric study performed on 830 patients treated according to the AIEOP-ALL BFM 2000 protocol, Basso et al. defined three risk groups with significantly different outcomes. The low risk group was defined by less than 10 -3 (0.1%) blast cells in the BM, comprised 42% of the patients and had a 5-year cumulative incidence of relapse of 7.5%.
Consistent with the PCR-based study of Panzer-Grümayer et al., 28 there was no relapse among patients with a d15 BM-MRD below 10 -4 in our study, but this group comprised only 13% of patients. Using the BM-MRD cut-off of 5x10 -3 , a larger low-risk group could be defined with a 5-year RFS of 97±3%. PB-MRD at the same time point in our study identified a similarly large (45%) low-risk group with a superior outcome, which only partially overlapped with the d15 BM low-risk group (Table 1) . This group consisted mostly of SR patients but also included IR patients and even one HR patient, as stratified by the ALL IC-BFM 2002 criteria that were based on age, WBC at diagnosis, prednisone response, and BM morphology status (M1-M3) at d15.
All previous d15 BM studies defined a high-risk group with an inferior outcome. The HR group defined by d15 BM-MRD over 10% (10 -1 ) comprised 11% of patients and had a 5-year cumulative incidence of relapse of 47±6% in the study of Basso et al. In a multivariate analysis including BFM PCR MRD stratification, the HR group by flow cytometry based on d15 was shown to be an independent risk factor. In the study of Sutton et al., 29 performed on patients treated in the Australian ANZCCSG Study VII, all patients with a d15 BM-MRD higher than 5x10 -2 relapsed. In this study, we applied a cut-off 10 -1 with a very similar result to that of Basso et al. (Figure 4B ). We tried to define a similar HR group using PB-MRD and used 10 -2 as a cut-off; however, neither BM nor PB distinguished the HR from the IR group with statistical significance ( Figure 4A, B) . This result was probably caused by a relatively low number of patients in our study.
Defining the low-risk group as early as d15 offers the possibility of early treatment deescalation (e.g., decreasing the dose of the anthracyclines used in the induction treatment in BFM-based protocols), although there are still no published data supporting this approach.
The main important technical issue for d15 MRD evaluation lies in the methodology used in this study. The introduction of a patient-specific RQ-PCR assay based on Ig/TCR clonal rearrangement is time demanding and requires at least two, but usually four, weeks from diagnosis, which would make an early treatment intervention based on d15 PCR MRD difficult. Flow cytometry, with its prompt results, would overcome this problem after rigorous standardization. However, it is premature to argue that our results would be also applicable to flow cytometry. Despite satisfactory PCR-flow correlation at d15 in our previous study, there was a substantial variation in individual pairs of samples, suggesting that the risk group definition based on either PCR or flow cytometry would be at least partly divergent. 31 Similarly to d15 BM-MRD studies, 28,30 also the d15 PB-MRD classification added prognostic information to the current BFM risk group stratification based on combined PCR MRD data from d33 and w12 in a bi-variate analysis. The large study of Basso et al. provided a platform for adding flow cytometric BM-MRD at d15 to the current BFM stratification based on PCR MRD at d33 and w12. Our study demonstrated that d15 PB would be similarly helpful in defining the low-risk group of patients as the d15 BM. However, it was not powered enough to elucidate whether d15 PB alone could also safely identify other HR patients on top of the d33 and w12 PCR classification, as did the d15 BM. 30 Larger study is needed to determine whether PB testing alone could replace the BM-MRD monitoring at d15.
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